Skip to content

MaxCyte MXCT Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin80.5%-0.7pp81.2%+1.2pp80%+0.2pp79.8%-1.1pp80.9%-0.7pp
Operating margin-141.8%+15.3pp-157.1%-1.5pp-155.6%-6.1pp-149.6%-13.6pp-135.9%-3.4pp
Net margin-121.2%+14.0pp-135.1%-2.6pp-132.6%-7.4pp-125.2%-14.3pp-110.9%-4.6pp
EBITDA margin-128.5%+15.5pp-144%-0.9pp-143.1%-5.6pp-137.5%-13.0pp-124.5%-3.2pp
Free cash flow margin-90.9%+18.6pp-109.5%+10.2pp-119.8%-12.8pp-107%-19.5pp-87.5%-11.7pp
Returns
Return on equity-21.3%+2.3pp-23.6%-0.4pp-23.2%-1.5pp-21.7%-2.1pp-19.6%-0.9pp
Return on assets-18.4%+1.8pp-20.2%-0.4pp-19.7%-0.7pp-19%-1.9pp-17.1%-1.0pp
Return on invested capital-25%+3.3pp-28.4%-0.2pp-28.2%-1.2pp-27%-2.5pp-24.5%+1.0pp
Efficiency
Asset turnover0.2×0.0×0.1×0.0×0.1×0.0×0.2×0.0×0.2×0.0×
Inventory turnover0.8×0.0×0.8×0.0×0.8×0.0×0.8×0.0×0.7×0.0×
Liquidity
Current ratio12×+3.7×8.3×+0.6×7.7×-4.7×12.4×+0.2×12.2×+1.3×
Quick ratio11.3×+3.5×7.8×+0.5×7.3×-4.4×11.7×+0.1×11.6×+1.3×
Cash ratio1.4×0.0×1.4×+0.6×0.8×-0.5×1.3×-0.5×1.8×+0.1×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$1.57-2.5%$1.61-4.7%$1.69-5.7%$1.79-4.8%$1.88-4.3%
Valuation
Market capitalization$130.15M-46.8%$165.34M-1.8%$168.44M-28.5%$235.5M-18.6%$289.46M-34.0%
Enterprise value$133.08M-46.3%$163.22M-6.0%$173.63M-27.3%$238.78M-16.2%$284.89M-33.6%
Price / sales-2.8×+0.1×4.9×-1.7×6.6×-1.1×7.7×-3.7×
Price / book0.8×-0.5×0.0×0.9×-0.3×1.2×-0.2×1.5×-0.7×
EV / sales4.1×-2.8×4.9×-0.1×-1.6×6.7×-0.9×7.6×-3.5×
Free cash flow yield-22.6%-6.9pp-21.9%+2.6pp-24.5%-8.2pp-16.2%-4.9pp-11.4%-4.7pp
Earnings yield-30.1%-11.7pp-27%+0.1pp-27.1%-8.1pp-19%-4.6pp-14.4%-5.1pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are MaxCyte's profit margins?
MaxCyte (MXCT) runs a 80.5% gross margin and a -141.8% operating margin, with a -121.2% net margin.
Where do MaxCyte's ratios come from?
Every ratio is computed from MaxCyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.